Supplemental Table I. Subject Baseline Characteristics- Between Group Comparisons

	Overall (N=397)	Usual Care (N=134)	Prevention Consult (N=130)	Prevention Consult + Behavioral Intervention (N=133)	P value	
Age	64.56 (10.76)	63.44 (11.28)	64.45 (11.05)	65.8 (9.86)	0.20	
Female sex	94 (23.68%)	30 (22.39%)	28 (21.54%)	36 (27.07%)	0.52	
Race					0.97	
White	272 (68.51%)	89 (66.42%)	91 (70%)	92 (69.17%)		
Black	56 (14.11%)	22 (16.42%)	17 (13.08%)	17 (12.78%)		
Asian	21 (5.29%)	8 (5.97%)	6 (4.62%)	7 (5.26%)		
Other	48 (12.09%)	15 (11.19%)	16 (12.31%)	17 (12.78%)		
Ethnicity					0.82	
Hispanic	34 (8.56%)	11 (8.21%)	10 (7.69%)	13 (9.77%)		
Non-Hispanic	363 (91.44%)	123 (91.79%)	120 (92.31%)	120 (90.23%)		
ВМІ	29.69 (5.1)	30.04 (5.24)	29.48 (5.08)	29.54 (5)	0.62	
Education					0.29	
≤High School Education	161(41.6%)	55 (41.98%)	46 (36.51%)	60 (46.15%)		
>High school Education	226 (58.4%)	76 (58.02%)	80 (63.49%)	70 (53.85%)		
Current Smoker	51 (12.85%)	18 (13.43%)	15 (11.54%)	18 (13.53%)	0.86	
Hypertension	315 (79.35%)	105 (78.36%)	102 (78.46%)	108 (81.2%)	0.81	
Hyperlipidemia	346 (87.15%)	115 (85.82%)	111 (85.38%)	120 (90.23%)	0.43	

Diabetes	126 (31.74%)	43 (32.09%)	35 (26.92%)	48 (36.09%)	0.28
Family History	168(42.53%)	54(40.91%)	58(44.62%)	56(42.11%)	0.83
Prior Angioplasty or Stent	154 (38.79%)	53 (39.55%)	55 (42.31%)	46 (34.59%)	0.43
Depression	49 (12.34%)	13 (9.7%)	17 (13.08%)	19 (14.29%)	0.50
Stress work/home					0.68
At least some	286(73.33%)	101(75.94%)	93(72.66%)	92(71.32%)	
Never	104 (26.67%)	32 (24.06%)	35(27.34%)	37(28.68%)	
Financial stress					0.81
At least moderate	150(38.66%)	51(38.64%)	52(40.63%)	47(36.72%)	
Little or None	238(61.34%)	81(61.36%)	76(59.38%)	81(63.28%)	
Medications at baseline					
Aspirin	319 (80.35%)	103 (76.87%)	108 (83.08%)	108 (81.20%)	0.43
Clopidogrel	146 (36.78%)	51 (38.06%)	46 (35.38%)	49 (36.84%)	0.90
Ace-inhibitors	107 (26.95%)	31 (23.13%)	32 (24.62%)	44 (33.08%)	0.14
Angiotensin-receptor blockers	109 (27.46%)	37 (27.61%)	40 (30.77%)	32 (24.06%)	0.48
Any Statin	279 (70.28%)	88 (65.67%)	92 (70.77%)	99 (74.44%)	0.29
High-intensity statin	103 (25.94%)	29 (21.64%)	33 (25.38%)	41 (30.83%)	0.23
Ezetimibe	21 (5.29%)	7 (5.22%)	7 (5.38%)	7 (5.26%)	0.99
Fish oil	51 (12.85%)	9 (6.72%)	16 (12.31%)	26 (19.55%)	0.007
Fibrates	21 (5.29%)	4 (2.99%)	5 (3.85%)	12 (9.02%)	0.06

Metformin	76 (19.14%)	26(19.40%)	21(16.15%)	29(21.80%)	0.51
PCI performed	376 (94.71%)	126 (94.03%)	125 (96.15%)	125 (93.98%)	0.6689

Family history defined as a first-degree relative with coronary artery disease; male <55 years old and female <65 years old; Ns reflect the number of patients per group assignment at baseline. ACE, angiotensin-converting enzyme; PCI, percutaneous coronary intervention

Supplemental Table II. Primary and Secondary Endpoints (Risk Factors)- Between Group Comparisons

Outcomes	Prevention	one vs Usual Care	Prevention Consult + Behavioral Intervention vs Usual Care					
	Unadjusted difference between groups	P value	Adjusted difference between groups	P value	Unadjusted difference between groups	P value	Adjusted difference between groups	P value
Δ Non-HDL-C (mg/dl)	-5.6 (-16.0, 4.9)	0.29	-5.2(-13.92,3.51)	0.24	1.5 (-9.01,11.9)	0.78	-5.77 (14.64,3.09)	0.2
Δ LDL-C (mg/dl)	-3.2 (-12.6, 6.3)	0.51	-3.28 (-11.1,4.54)	0.41	-1.4 (-10.9, 8.04)	0.77	-8.09 (-16.04,-0.15)	0.05
Δ Total Cholesterol	-7.0 (-17.5, 4.0)	0.22	-6.02(-15.1,3.06)	0.19	-1.5 (-12.3, 9.2)	0.78	-8.81 (-18.04,0.42)	0.06
Δ Triglycerides	-10.0 (-37.3,17.4)	0.47	-11.65 (-31.99,8.69)	0.26	22.8 (-4.7, 50.2)	0.1	12.81 (-7.85,33.47)	0.22
Δ HbA1C	0.16 (-0.08, 0.4)	0.2	0.19 (-0.05,0.42)	0.11	0.19 (-0.05, 0.43)	0.13	0.16 (-0.07,0.4)	0.17
Δ Weight (kg)	-0.37 (-1.9,1.2)	0.64	-0.45 (-2.02,1.12)	0.57	0.08 (-1.5, 1.6)	0.92	-0.17 (-1.74,1.4)	0.83
Δ BMI (kg/m2)	-0.05 (-0.58, 0.49)	0.86	-0.06 (-0.6,0.48)	0.83	0.03 (-0.5, 0.56)	0.9	-0.03 (-0.57,0.5)	0.91
Δ SBP (mmHg)	0.81 (-4.7, 6.3)	0.77	-1.15 (-5.69,3.39)	0.62	-1.4 (-6.8, 4.0)	0.61	-4.76 (-9.29,-0.24)	0.04
Δ DBP (mmHg)	1.2 (-2.6, 4.9)	0.54	-0.45 (-3.35,2.46)	0.76	-1.4 (-5.04, 2.3)	0.46	-2.53 (-5.42,0.36)	0.19

HbA_{1C}, Hemoglobin A1C; Non-High-density lipoprotein-calculated; LDL-C, Low-density lipoprotein- calculated; HDL, High-density lipoprotein; BMI, Body Mass Index; SBP, Systolic blood pressure; DBP, Diastolic blood pressure

Supplemental Table III. Secondary Endpoints (Lifestyle Factors)-Between Group Comparisons

Outcomes	Prevention	one vs Usual Care	Prevention Consult + Behavioral Intervention vs Usual Care					
	Unadjusted difference between groups	P value	Adjusted difference between groups	P value	Unadjusted difference between groups	P value	Adjusted difference between groups	P value
Δ Quality of life	-0.01 (-0.04,0.03)	0.75	0.02 (-0.06, 0.01)	0.22	-0.01 (-0.04,0.03)	0.62	-0.02 (-0.05,0.02)	0.28
Δ Yale physical activity	-3.8 (-11.1, 3.54)	0.31	0.28 (-7.4, 6.9)	0.94	-3.41 (-9.86,3.05)	0.3	-2.36 (-8.71,3.99)	0.47
Δ Saturated fat intake	0.36 (-1.11, 1.83)	0.63	-0.63 (-2.1, 0.8)	0.39	-0.44 (-1.73,0.86)	0.51	0.51 (-1.77,0.76)	0.43
Δ Fruit & Vegetable Intake	-0.04 (-0.54, 0.45)	0.87	0.06 (-0.42, 0.55)	0.8	-0.15 (-0.6, 0.29)	0.5	-0.05 (-0.05,0.39)	0.81
Δ Medication Adherence	-0.15 (-0.43, 0.13)	0.28	-0.25 (0.53, 0.02)	0.07	-0.35 (-0.94, 0.25)	0.25	0.01 (-0.59, 0.6)	0.98
Δ Patient health questionnaire	0.15 (-0.61, 0.91)	0.7	-0.19 (-0.94, 0.56)	0.63	0.29 (-0.34, 0.92)	0.37	0.07 (-0.56, 0.69)	0.83

Quality of life measured by EQ5D survey; Physical Activity measured by Part 2 of Yale Physical Activity Questionnaire; Saturated fat measured by NWLRC Fat Intake Survey; fruit and vegetable intake measured by Fruit and Vegetable Intake Screener; medication adherence defined by Morisky Scale; patient health defined by Personal Health Assessment Questionnaire

Supplemental Table IV. Differences in Baseline Characteristics in Patients with and without Follow-up Data at 6 months

	With follow-	Missing follow-	
	up data	up data	P value
	N=317	N=80	
Age	65.16(10.35)	62.18(12.04)	0.04
Female sex	75(23.66%)	19(23.75%)	0.99
Race			0.76
White	217(68.45%)	55(68.75%)	
Black	46(14.51%)	10(12.5%)	
Asian	15(4.73%)	6(7.5%)	
Other	39(12.3%)	9(11.25%)	
Ethnicity			0.20
Hispanic	30(9.46%)	4(5%)	
Non-Hispanic	287(90.54%)	76(95%)	
ВМІ	29.74(5.15)	29.5(4.92)	0.70
Education			0.02
≥ High school Education	301(97.41%)	71(91.03%)	
< High School Education	8(2.59%)	7(8.97%)	
Risk Factors			
Current Smoker	36(11.36%)	15(18.75%)	0.08
Hypertension	251(79.18%)	64(80%)	0.87
Hyperlipidemia	273(86.12%)	73(91.25%)	0.22
Diabetes	95(29.97%)	31(38.75%)	0.13
Family history(any)	138(43.81%)	30(37.5%)	0.31
Prior Angioplasty or Stent	123(38.8%)	31(38.75%)	0.99
Depression	49(15.61%)	9(12%)	0.43
Stress work/home			0.10
At least some	236(75.16%)	50(65.79%)	
Never	78(24.84%)	26(34.21%)	
Financial Stress			0.53
At least moderate	123(39.42%)	27(35.53%)	
Little or None	189(60.58%)	49(64.47%)	
Medications			
Aspirin	247(77.92%)	72(90%)	0.02

Clopidogrel	116(36.59%)	30(37.5%)	0.88
ACE-inhibitors	85(26.81%)	22(27.5%)	0.90
Angiotensin-receptor blockers	87(27.44%)	22(27.5%)	0.99
Any Statin	217(68.45%)	62(77.5%)	0.11
High Intensity	81(25.55%)	22(27.5%)	0.72
Ezetimibe	17(5.36%)	4(5%)	1.00
Fish oil	39(12.3%)	12(15%)	0.52
Fibrates	20(6.31%)	1(1.25%)	0.09
Metformin	58(18.3%)	18(22.5%)	0.39
PCI performed	299(94.32%)	77(96.25%)	0.78

[&]quot;Missing follow-up data" reflects subjects missing either baseline or 6 month data including 3 in PC and 1 in UC who died prior to 6 month follow-up.

Supplemental Table V. Total Number of Patients Missing Data at 6 Months for each endpoint

Variable Name	Usua	l care	Preventi	on Consult	Total N	Total missing
	N	Missing follow-up data	N	Missing follow-up data		
Non-HDL	104	30	213	50	317	80
LDL	102	32	212	51	314	83
TC	104	30	213	50	317	80
TG	104	30	213	50	317	80
HbA1c	90	44	192	71	282	115
Weight	99	35	212	51	311	86
BMI	99	35	212	51	311	86
SBP	102	32	212	51	314	83

DBP	102	32	212	51	314	83
		~ —				

N reflects the number of patients with data at both baseline and 6 month time point for each endpoint. "Missing follow-up data" reflects subjects missing either baseline or 6 month data including 3 in PC and 1 in UC who died prior to 6 month follow-up.